3
Announcements
Trials
Browse
Landscape
Phase
Phase 4
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
10
Thoracic
2
Breast
2
Genitourinary
1
Dermatologic
1
Conditions
Prostatic Neoplasms
4
Urinary Bladder Neoplasms
3
Neoplasms
1
Melanoma
1
Lung Neoplasms
1
Kidney Neoplasms
1
Emergence Delirium
1
Delirium
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Breast Neoplasms
1
Interventions
pembrolizumab
6
sargramostim
5
Psychiatric Rehabilitation
5
Early Intervention, Educational
5
Magnetic Resonance Spectroscopy
4
Gemcitabine
4
Cyclophosphamide
4
palbociclib
3
Trastuzumab
3
Therapeutics
3
Standard of Care
3
Radiotherapy
3
Oxaliplatin
3
Methods
3
Irinotecan
3
Interferon-alpha
3
Fluorouracil
3
Fluorodeoxyglucose F18
3
Erlotinib Hydrochloride
3
Docetaxel
3
Bortezomib
3
temsirolimus
2
motexafin gadolinium
2
entinostat
2
cemiplimab
2
cediranib
2
Specimen Handling
2
Radiosurgery
2
Practice Guidelines as Topic
2
Paclitaxel
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Colonic Neoplasms
×
Propofol
×
Genitourinary
×
Clear all
NCT04074460
2022-06-09
VAPOR-C
Peter MacCallum Cancer Centre, Australia
Phase 4
Completed
169 enrolled